Wall Street analysts expect Becton Dickinson (BDX) to post quarterly earnings of $3.42 per share in its upcoming report, which indicates a year-over-year decline of 2.3%. Revenues are expected to be $5.48 billion, up 9.9% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.6% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Becton Dickinson metrics that Wall Street analysts commonly model and monitor.
Analysts forecast 'Revenues- BD Interventional' to reach $1.30 billion. The estimate suggests a change of +4.9% year over year.
The consensus among analysts is that 'Revenues- BD Interventional- Surgery' will reach $392.40 million. The estimate points to a change of +4.4% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- BD Interventional- Peripheral Intervention' should arrive at $510.63 million. The estimate indicates a change of +4.6% from the prior-year quarter.
Analysts expect 'Revenues- BD Interventional- Urology and Critical Care' to come in at $397.09 million. The estimate suggests a change of +5.9% year over year.
Analysts' assessment points toward 'Revenues- BD Medical- Medication Management Solutions- International' reaching $166.23 million. The estimate points to a change of +3.9% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- BD Life Sciences- Biosciences- International' will likely reach $215.77 million. The estimate indicates a year-over-year change of -2.8%.
According to the collective judgment of analysts, 'Revenues- BD Interventional- Peripheral Intervention- United States' should come in at $272.88 million. The estimate indicates a change of +3.8% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- BD Interventional- Urology and Critical Care- United States' of $315.60 million. The estimate points to a change of +6.3% from the year-ago quarter.
The average prediction of analysts places 'Revenues- BD Interventional- United States' at $882.06 million. The estimate indicates a change of +4.5% from the prior-year quarter.
It is projected by analysts that the 'Revenues- BD Interventional- Surgery- International' will reach $98.18 million. The estimate indicates a change of +5.6% from the prior-year quarter.
Analysts predict that the 'Revenues- BD Interventional- Peripheral Intervention- International' will reach $236.41 million. The estimate indicates a change of +5.1% from the prior-year quarter.
The consensus estimate for 'Revenues- BD Interventional- Urology and Critical Care- International' stands at $82.51 million. The estimate suggests a change of +5.8% year over year.
View all Key Company Metrics for Becton Dickinson here>>>Over the past month, Becton Dickinson shares have recorded returns of +0.1% versus the Zacks S&P 500 composite's +0.6% change. Based on its Zacks Rank #4 (Sell), BDX will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks Names #1 Semiconductor Stock
This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.
See This Stock Now for Free >>Becton, Dickinson and Company (BDX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
